German based pharma major-Boehringer Ingelheimand Lupin today announced the expansion of their partnership with plans to market two new oral anti-diabetics recently approved by the Drugs Controller General of India (DCGI)-Gibtulio Met (Empagliflozin+ Metformin) and Ajaduo (Empagliflozin +Linagliptin).

Both these products belong to a novel class of oral anti-diabeticdrugs patented in India and will be launched forthe firsttime by an Indian company. The two products will be comarketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names.

Rajeev Sibal, President, India Region Formulations, Lupin, "We are excited about the expansion of our partnership with Boehringer Ingelheim and our combined contribution to combating the increasing incidence of Diabetes in India. The introduction of thesetwo neworal anti-diabeticstothe market will strengthen ouranti-diabetes portfolio and will contribute immensely to our position as a leading player inthe Indian pharmaceutical market.''

Shares of the company declined Rs 9.75, or 1.07%, to trade at Rs 902.20. The total volume of shares traded was 32,827 at the BSE (10.09 a.m., Wednesday).